We investigated prevalence of lymphogranuloma venereum (LGV) among men who have sex with men who were tested for chlamydia at 12 clinics in the United Kingdom during 10 weeks in 2012. Of 713 men positive for Chlamydia trachomatis, 66 (9%) had LGV serovars; 15 (27%) of 55 for whom data were available were asymptomatic.

Word count: 15642 ABSTRACT (word count 212)

HIV partner notification (PN) is a highly effective strategy to identify people living with undiagnosed HIV infection. This national audit of HIV PN is against the 2015 British Association of Sexual Health and HIV (BASHH)/British HIV Association (BHIVA)/Society of Sexual Health Advisers (SHAA)/National AIDS Trust (NAT) HIV PN standards, developed in response to the 2013 BASHH/BHIVA national HIV PN audit. We report significant improvements in the number of contacts tested per index case, likely due, in part, to clearer definitions as well as better ascertainment and reporting. There remains scope for improvement with informing and testing contactable contacts. Recommendations from this audit include further refinement of definitions and development of a national proforma for HIV PN.

Background Homosexual men have high rates of anal cancer but an understanding of the epidemiology of HSIL, the presumed precursor, is lacking. We aimed to describe the epidemiology of anal HSIL, and association with human papillomavirus (HPV), in a community-recruited cohort of homosexual men. Methods The Study of the Prevention of Anal Cancer is a threeyear prospective study of anal HPV infection and cancer precursors in homosexual men aged ≥ 35. At each visit all men receive an anal swab for cytology and HPV genotyping (Roche Linear Array), and high resolution anoscopy with biopsy of suspected lesions. Anal HSIL was defined as having either intraepithelial neoplasia grade 2/3 on histology and/or HSIL on cytology. Results 293 men were recruited by December 2012. Median age was 49 and 28.3% were HIV-positive. The baseline prevalence of anal HSIL was 44.6% and 34.8% in the HIV-positive and -negative respectively (p = 0.119). Among those without HSIL at baseline, HSIL incidence was 30.0 and 20.0 per 100 person-years in the HIVpositive and -negative (p = 0.467). Among those with HSIL at baseline, the clearance rate was 37.0 and 44.1 per 100 person-years in the HIV-positive and -negative (p = 0.771). Men who tested HPV16 positive on their anal swab at baseline were more likely to develop incident HSIL (58.1 vs 16.1 per 100 person-years, p = 0.002), and less likely to clear prevalent HSIL (15.9 vs. 65.9 per 100 person-years, p = 0.006). Conclusion Anal HSIL were highly prevalent. Incidence and clearance were common and closely associated with HPV16 status. The high rate of clearance is consistent with the observation that anal HSIL progress to cancer less commonly than do cervical HSIL. The close association of persistence with HPV16 status suggests that HPV testing should be investigated as a means of identifying those with HSIL who are at highest risk of developing cancer. LGV cases (55%) were HIV-positive. Through EPIS STI, 279 male and 2 female cases from additional 6 countries were reported, mainly in capital areas. Symptoms were reported for 132 cases: 105 cases with and 27 without symptoms. EPidEmic of LymPhoGrAnuLomA VEnErEum (LGV) in EuroPE P3.136Proctitis was most commonly reported in men. Among those with known HIV status, 80% were HIV positive. 45% of cases in Spain were in migrants and 20% of the UK cases reported sexual contacts abroad. Conclusions LGV remains to be primarily found in HIV positive MSM. Asymptomatic presentation hampers case detection and screening and routine genotyping among MSM were suggested to reduce further transmission of LGV. Screening practises differ across countries which results in diversity in number and nature of reported cases. Countries reported individual and clustered LGV cases in EPIS STI with more detailed information than in routine surveillance reports to ECDC. Efforts were made to increase European collaboration to get a better understanding of the evolving LGV epidemic in Europe. Background Lubricants (lube) used during receptive anal intercourse (RAI) may affect ...

IntroductionMorbidity and mortality rates from AIDs defining cancers have fallen significantly since the introduction of highly active antiretroviral therapy (HAART). Patients are now living longer with HIV and are at a greater risk of other HIV- and non-HIV related malignancies. We report what we believe to be the first UK cancer prevalence study in the modern HAART era.MethodsA retrospective review of electronic clinic letters was performed for all patients currently receiving, and those who had died whilst receiving, their HIV care at our centre. Demographics of patients with pre-cancerous changes, an active or previous cancer were recorded.ResultsThere were 438 active patients (369 male, 69 female) and 18 deceased patients (12 male, 6 female) in April 2014. Thirty-six out of four hundred fifty-six (8%) cancer diagnoses were found overall. Thirty-one out of four hundred thirty-eight (7%) diagnoses in active patients and 5/18 (28%) in deceased patients. More than half of those diagnosed with cancer were aged 50 or over (17/31 [55%]). In active patients 17/31 (55%) were AIDs defining cancers, with the most common type of cancer diagnosis overall being Kaposi's sarcoma (12/31 [39%]). There were 5/31 (16%) cases of non-Hodgkin's lymphoma. The most common non-AIDs defining cancer was basal cell carcinoma of which there were 5/31 (16%) cases, followed by squamous cell carcinoma (3/31 [10%]) and testicular cancer (3/31 [10%]). Other cancers included colorectal (2/31 [6%]) and prostate cancer (1/31 [3%]). In all five deceased patients, cancer was the cause of death. There were four acute presentations with an aggressive glioma, Burkitt's lymphoma, an undiagnosed primary lung malignancy and a late diagnosed cervical cancer. The fifth patient died following the recurrence of a transitional cell cancer of the bladder after an initial diagnosis of seven years earlier. Eighteen out of sixty-nine (26%) of females were found to have at least mild dyskariosis on cervical screening. Anal intraepithelial neoplasia was diagnosed in 4/438 (1%) of patients.ConclusionsNon-AIDS defining malignancies account for almost half of the cancers in our cohort. This number may rise further as patients live longer with HIV. Good communication between oncologists and HIV physicians is paramount to manage the complex interactions of HIV and cancer, increase HIV testing in cancer services and address cancer risk factors in existing HIV patients.